Search results
Showing 16 to 28 of 28 results for ibs
Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
This quality standard covers diagnosing, assessing and managing food allergy in children and young people (under 19) and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS118Show all sections
Sections for QS118
- Quality statements
- Quality statement 1: Allergy-focused clinical history
- Quality statement 2: Diagnosing IgE-mediated food allergy
- Quality statement 3: Diagnosing non-IgE-mediated food allergy
- Quality statement 4: Referral to secondary or specialist care
- Quality statement 5 (placeholder): Diagnosing food allergy in adults
- Quality statement 6 (placeholder): Nutritional support for food allergy
- Update information
This guidance has been updated and replaced by NICE healthtech guidance 598.
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)
This evidence summary has been updated and replaced by NICE guideline CG61.
Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)
We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.
This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.